n-Butyl 1-aminomethyl-1-cyclohexane-acetate | 138799-99-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: n-Butyl 1-aminomethyl-1-cyclohexane-acetate
• 英文别名: Butyl 2-[1-(aminomethyl)cyclohexyl]acetate
• CAS: 138799-99-2
• 化学式: C₁₃H₂₅NO₂
• 分子量: 227.347
• InChiKey: IPNWNGVBVWEYLT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  16
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  烟酸 、 n-Butyl 1-aminomethyl-1-cyclohexane-acetate 在 N,N'-二环己基碳二亚胺 作用下， 生成
  参考文献：
  名称：

  Namdeo; Shrivastava, Sushant K., Asian Journal of Chemistry, 2011, vol. 23, # 4, p. 1861 - 1862

  摘要：

  DOI：

文献信息

• [EN] 4-T-BUTYLGABAPENTIN AND ITS SYNTHESIS<br/>[FR] 4-T-BUTYLGABAPENTINE ET SYNTHESE DE CE COMPOSE
  申请人：HIKAL LTD

  公开号：WO2005087709A1

  公开（公告）日：2005-09-22

  The present invention relates to compounds cis (Z) and trans (E) stereoisomers of 4-t-butylgapentin of formula (11) and (12) and a process for the preparation of the said stereoisomers.

  本发明涉及公式（11）和（12）的4-叔丁基加巴喷丁的顺式（Z）和反式（E）立体异构体化合物以及所述立体异构体的制备方法。
• Oral Pharmaceutical Compositions of Buprenorphine and Method of Use
  申请人：BABUL Najib

  公开号：US20120178771A1

  公开（公告）日：2012-07-12

  The present invention is directed to oral, therapeutically effective pharmaceutical compositions of buprenorphine and it pharmaceutically acceptable salts and the use thereof, including delayed onset and controlled release dosage forms. The present invention is also directed delayed onset, rapid release dosage forms and delayed onset, extended release dosage forms of oral buprenorphine which provide robust efficacy and reduced potential for abuse and misuse.

  本发明涉及布洛芬静脉注射剂的制备方法，其特点在于提供了一种口服的、治疗有效的布洛芬药物组合物，包括布洛芬及其药学上可接受的盐，并且包括延迟发挥和控制释放的剂型。本发明还涉及口服布洛芬的延迟发挥、快速释放和延迟发挥、持续释放剂型，这些剂型提供了强大的疗效，并减少了滥用和误用的潜在风险。
• Gabapentin and its derivatives for treating neurodegenerative diseases
  申请人：WARNER-LAMBERT COMPANY

  公开号：EP0446570A2

  公开（公告）日：1991-09-18

  The instant invention is novel uses of known cyclic amino acids. Such compounds as gabapentin are used for treating neurodegenerative disorders, perinatal asphyxia, status epilepticus, Alzheimer's, Huntington's, Parkinson's, and Amyotrophic Lateral Sclerosis.

  本发明是已知环状氨基酸的新用途。加巴喷丁等化合物可用于治疗神经退行性疾病、围产期窒息、癫痫状态、阿尔茨海默氏症、亨廷顿氏症、帕金森氏症和肌萎缩侧索硬化症。
• Delivery system for cyclic amino acids with improved taste, texture and compressibility
  申请人：WARNER-LAMBERT COMPANY

  公开号：EP0458751A1

  公开（公告）日：1991-11-27

  A new delivery system for cyclic amino acid compounds and the process for its preparation is disclosed, which has use in a variety of products including comestibles such as chewing gum compositions, confections, and pharmaceutical such as chewable tablets. More particularly, this invention relates to a process for preparing a delivery system that provides enhanced masking of the bitter flavour characteristic of the active, reduced grittiness, retained stability at the elevated temperatures of product formulation, and improved compressibility for formation into tablets.

  本发明公开了一种新的环状氨基酸化合物给药系统及其制备工艺，该系统可用于多种产品，包括口香糖组合物、糖果等零食和咀嚼片等药物。更具体地说，本发明涉及一种制备给药系统的工艺，这种给药系统能增强对活性物质苦味特征的掩盖，减少粗糙度，在产品配方的高温下保持稳定，并提高压缩性以制成片剂。
• Stable solid dosage forms of amino acids and processes for producing same
  申请人：——

  公开号：US20020091159A1

  公开（公告）日：2002-07-11

  Pharmaceutical formulations, and processes for making same, comprising an amino acid which is liable to formation of an undesirable lactam, and a stabilizer comprising a volatile alcohol; a non-volatile alcohol; a water immiscible liquid or solid; a liquid with a relatively low dielectric constant; a liquid surface active agent; a solid surface active agent; an antioxidant; a ketone; an aldehyde; a solid polyethylene glycol of high molecular weight; polyvinylpyrrolidone; a derived cellulose; silicon dioxide; or a combination thereof.

  药物制剂及其生产工艺，包括一种易形成不良内酰胺的氨基酸和一种稳定剂，稳定剂包括挥发性醇；非挥发性醇；不溶于水的液体或固体；介电常数相对较低的液体；液体表面活性剂；固体表面活性剂；抗氧化剂；酮；醛；高分子量的固体聚乙二醇；聚乙烯吡咯烷酮；衍生纤维素；二氧化硅；或它们的组合。